Harvard Bioscience Continues To Expect 2024 Gross Margin Of Approximately 60% And Adjusted EBITDA Margin In The Mid-teens

For the full year 2024 revenues to be approximately flat versus 2023. Company sees second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in China. The company seest 2024 gross margin of approximately 60% and adjusted EBITDA margin in the mid-teens.